Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prosp
In previously virologically suppressed PWH on an EFV-based regimen, the switch to DOR/3TC/TDF maintained virological suppression noninferior to that of BIC/FTC/TAF, with favorable metabolic profiles.
Authors
- L. Liu
- Aixin Li (ORCID: https://orcid.org/0000-0002-3158-0170)
- Jiangzhu Ye (ORCID: https://orcid.org/0000-0002-4456-7960)
- Zaicun Li (ORCID: https://orcid.org/0009-0005-0773-3316)
- Jianwei Li (ORCID: https://orcid.org/0000-0003-4353-0960)
- Xing Wang (ORCID: https://orcid.org/0000-0002-8537-7186)
- Liang Wu (ORCID: https://orcid.org/0000-0003-2521-7348)
- Lili Dai
- Yue Gao
- Yanwei Yao
- Hongwei Zhang
- Lijun Sun
- An Liu
Institutions
- Chinese Center For Disease Control and Prevention (CN)
- Chifeng Municipal Hospital (CN)
- National Center for AIDS/STD Control and Prevention,China CDC (CN)
- Beijing YouAn Hospital (CN)
- Beijing Ditan Hospital (CN)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1093/ofid/ofaf808
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00